Investor Presentation: First Nine Months of 2020
29
Investor presentation
First nine months of 2020
Novo Nordisk®
Pipeline supports significant growth opportunities across all four
strategic focus areas
PHASE 1
NN1535 Icosema (LAIsema)
NN1965 - Insulin 965
NN1147 Insulin 147
NN9389QW Sema + GIP
NN1845 Glucose sensitive
insulin
NN9775 PYY 1875 analogue
NN9215 LA-GDF15
NN9838 - AM833 and Sema
NN7769 Mim8 (Phase 1/2)
NN7533 Eclipse
NN9500 FGF-21 NASH
NN6434 PCSK9i
NN6177 - GG-co-agonist
PHASE 2
NN1436 Icodec (LAI287)
NN9838-Amylin AM833
EX2020 Macrilen, GHD5
NN9931 - Semaglutide NASH
NN9931 - Gilead NASH
NN6018 - Ziltivekimab
PHASE 3
SUBMITTED
Semaglutide obesity
Somapacitan - QW AGHD¹
SELECT Semaglutide 2.4 mg in
obesity CVOT
Somapacitan - QW GHD2
Concizumab
SUSTAIN FORTE - Semaglutide 2.0 mg
SOUL - Oral semaglutide CVOT
FLOW - Semaglutide 1.0 mg in
chronic kidney disease
FOCUS Semaglutide 1.0 mg in
diabetic retinopathy
APPROVED
Tresiba
Ⓡ
XultophyⓇ
LevemirⓇ
RyzodegⓇ
NovoMixⓇ
FiaspⓇ
NovoRapidⓇ
VictozaⓇ
OzempicⓇ
RybelsusⓇ3
SaxendaⓇ
NovoSevenⓇ
NovoEight®
STT-5058
STATEN, ApoC3 mAb
Diabetes
Obesity
Haemophilia
Growth Disorders
NovoThirteenⓇ
RefixiaⓇ/RebinynⓇ
NorditropinⓇ
SogroyaⓇ6
Other serious chronic disease
1 Study conducted in adult growth hormone disorder; 2 Study conducted in growth hormone disorders; 3 Approved in the US, the EU, and Japan; submitted in Canada; 4 Study conducted in NASH; 5 Novo Nordisk only holds the commercial rights in North
America; Approved in the US
LAIsema: Long-acting insulin combined with semaglutide; PYY: Peptide YY; QW: Once-weekly; GG: Glucagon GLP-1; mAb: monocolonal antibody; GDF15: Growth differentiation factor 15; Sema: Semaglutide; FGF-21: Fibroblast growth factor 21; LAI: Long-acting
insulin; AGHD: Adult growth hormone disease; GHD: Growth hormone disorder; lira: Liraglutide; Note: the obesity co-agonist and tri-agonist projects have been terminatedView entire presentation